[A compounding agent of alogliptin and pioglitazone].
Type 2 diabetes is characterized by insulin resistance and pancreatic beta cell dysfunction, and the latter is known to usually progress during the entire disease history. Thus, monotherapy cannot ameliorate both aspects of these and often fails to achieve the target level of glucose control. Pioglitazone, a thiazolidinedione class agent, is an insulin sensitizer and alogliptin belongs to DPP-4 (dipeptidyl peptidase-4) inhibitor class agents, which promote postprandial insulin secretion and suppress glucagon secretion in a blood glucose dependent fashion. Both agents have been shown to protect beta cell from apoptosis in animal models, which is one of major causes of beta cell dysfunction in human. Therefore, the combination therapy or more ideally a compounding agent of pioglitazone and alogliptin is expected to be effective and beneficial for a large number of people with type 2 diabetes in terms of strict glycemic control.